Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1

被引:0
|
作者
A. Krongrad
E. Atochina
J. W. Ryan
B. A. Roos
机构
[1] University of Miami School of Medicine,Department of Urology (112)
[2] and Geriatric Research,Department of Medicine, Sylvester Comprehensive Cancer Center
[3] Education,Department of Neurology
[4] and Clinical Center,undefined
[5] University of Miami School of Medicine,undefined
[6] University of Miami School of Medicine,undefined
[7] and Geriatric Research,undefined
[8] Education,undefined
[9] and Clinical Center,undefined
来源
Urological Research | 1997年 / 25卷
关键词
Prostate cancer; Endopeptidase 24.11; Growth; LNCaP; PPC-1;
D O I
暂无
中图分类号
学科分类号
摘要
Human endopeptidase 24.11 (EP) occurs in greatest abundance on terminally differentiated prostate cells; thus, loss of EP could mark dedifferentiation of prostate epithelium. To identify laboratory models that would permit continuous work on the biochemistry and hormonal regulation of EP, we examined the well-differentiated LNCaP and poorly differentiated PPC-1 human prostate cancer cell lines. Ultrastructural analysis revealed that LNCaP secretes electron-dense material that resembles the particulate matter of seminal plasma, which is associated with endopeptidase activity. LNCaP medium contained EP activity while PPC-1 medium did not. Whether the apparent deletion of EP from the PPC-1 cell line is characteristic of poorly differentiated prostate adenocarcinoma is not yet clear. However, it may be relevant to the carcinogenic process that EP can limit growth of lung small carcinomas by inactivating cell growth-promoting bombesin-like peptides. Because bombesin has been identified in aggressive human prostate cancers, loss of EP in PPC-1 could represent a necessary step in transformation to aggressive phenotype. The combination of LNCaP and PPC-1, which offers well-differentiated and poorly differentiated cancer phenotypes, appears well suited to studying the relevance of EP in prostate cancer biology.
引用
收藏
页码:113 / 116
页数:3
相关论文
共 50 条
  • [1] Endopeptidase 24.11 activity in the human prostate cancer cell lines LNCaP and PPC-1.
    Krongrad, A
    Atochina, E
    Ryan, JW
    Roos, BA
    UROLOGICAL RESEARCH, 1997, 25 (02): : 113 - 116
  • [2] CHROMOSOME IDENTITY OF HUMAN PROSTATE-CANCER CELL-LINES, PC-3 AND PPC-1
    CHEN, TR
    CYTOGENETICS AND CELL GENETICS, 1993, 62 (2-3): : 183 - 184
  • [3] Suppression of the malignant phenotype of human prostate cancer cell line PPC-1 by introduction of normal fragments of human chromosome 10
    Murakami, YS
    Albertsen, H
    Brothman, AR
    Leach, RJ
    White, RL
    CANCER RESEARCH, 1996, 56 (09) : 2157 - 2160
  • [4] Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells
    Sak, Katrin
    Lust, Helen
    Kase, Marju
    Saar, Marika
    Jaal, Jana
    ANTICANCER RESEARCH, 2018, 38 (11) : 6209 - 6215
  • [5] Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin-converting enzyme in human prostate cancer cell lines
    Usmani, BA
    Harden, B
    Maitland, NJ
    Turner, AJ
    CLINICAL SCIENCE, 2002, 103 : 314S - 317S
  • [6] Antiandrogenic activity of Riboflavin 5′-phosphate (FMN) in 22Rv1 and LNCaP human prostate cancer cell lines
    Choi, Yun-Ho
    Kim, Jaeyoon
    Shin, Jae Young
    Kang, Nae-Gyu
    Lee, Sanghwa
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2022, 917
  • [7] Possible Antiproliferative Effect of Tolfenamic Acid on Human LNCaP Prostate Cancer Cell Lines
    Ertekin, Rifat
    Ozkurt, Mete
    Kus, Gokhan
    Kabadere, Selda
    PAKISTAN JOURNAL OF ZOOLOGY, 2019, 51 (04) : 1413 - 1419
  • [8] Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity
    David-Beabes, GL
    Overman, MJ
    Petrofski, JA
    Campbell, PA
    De Marzo, AM
    Nelson, WG
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2000, 17 (06) : 1077 - 1086
  • [9] Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines
    Liu, AY
    Brubaker, KD
    Goo, YA
    Quinn, JE
    Kral, S
    Sorensen, CM
    Vessella, RL
    Belldegrun, AS
    Hood, LE
    PROSTATE, 2004, 60 (02): : 98 - 108
  • [10] Selective ETA receptor antagonist YM598 inhibits ET-1-induced cell signaling and cell growth in hormone refractory human prostate cancer cell line, PPC-1
    Watanabe, M
    Yuyama, H
    Fujimori, A
    Mori, M
    Sato, S
    Sudoh, K
    Sasamata, M
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2005, 97 : 258P - 258P